

Research Instruments and Universiti Putra Malaysia invite you to our seminar:

“Advanced Emerging Technologies for the Efficient Capture and Characterization of Circulating Tumor Cells (CTCs)”

Presented by:

Thomas J. Murphy, Ph.D.
Chief Scientific Officer

Venue: Medical Library Auditorium
Faculty of Medicine and Health Sciences
UPM

Date: 15 December 2014 (Monday)

Time: 2.30pm – 4.00pm



**Register Now
It's Free**

Refreshments Available


SEMINAR ABSTRACT:

Circulating tumor cells (CTCs) are rare cells found in the blood of cancer patients with solid tumors and play a key role in cancer dissemination. There has been considerable interest in analyzing these cells as a potential source of clinically-actionable information relating to the molecular profile of the patient's disease. This so-called "liquid biopsy" therefore potentially offers a window into the specific molecular aberrations present in the primary tumor while avoiding a physical biopsy. It also presents itself as an attractive method to repeatedly monitor the progression/regression of disease during therapeutic intervention.

In this seminar, Dr. Thomas Murphy will describe methods to capture CTCs utilizing a microfluidic magnetic bead affinity-capture technology (IsoFlux, Fluxion Biosciences) and a picoliter droplet-based genomic analysis platform (RainDrop System, RainDance Technologies) to characterize tumor cells using digital PCR and next-gen sequencing. Case studies will also be highlighted to demonstrate how these technologies are applied in practice in CTC research.

ABOUT THE SPEAKER:

Dr. Thomas Murphy is a cell biologist with over 15 years' experience in molecular cell biology and target identification and validation. His particular research interests include biological imaging, cell signaling, and angiogenesis. Prior to joining Research Instruments, Dr. Murphy worked as an Applications Scientist at Thermo Scientific (Dharmacon RNAi Technologies), where he functioned as a subject matter expert in the field of RNA interference and provided specialist knowledge for fellow scientists using RNAi technology. During his post-doctoral fellowship, he worked at the Novartis Institute for Functional Genomics (GNF) in San Diego, where he was responsible for conceiving and implementing siRNA-based genomic screens against inflammatory and oncology pathways. He received his B.A. in Biology from Occidental College, followed by his Ph.D. from the Molecular Biology Institute at University of California, Los Angeles. He has also held research positions at UC San Francisco and Amgen Inc. Dr. Murphy is currently Chief Scientific Officer at Research Instruments and heads their Life Science applications team. He is also General Manager of Origen Laboratories, a laboratory service provider which specializes in providing genomics-related services.



For registration, please contact:
Nicholas
Phone: 017-6307837
Email: nicholas.siew@ri.com.my

